Cargando…
Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study
BACKGROUND: Anlotinib is used as a third-line treatment for advanced non-small-cell lung cancer (NSCLC), but has limited clinical benefits and several side effects, such as diarrhea and acneiform skin rash. Traditional Chinese Medicine (TCM) is commonly used to treat cancers in China. Chinese herbal...
Autores principales: | Chen, Wenmin, Lin, Jietao, Yang, Ting, xin Zhang, Ze, Tao, Lanting, Xiao, Zhiwei, Chen, Hanrui, Qi, Xiangjun, Sun, Lingling, Cao, Yang, Lin, Lizhu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893062/ https://www.ncbi.nlm.nih.gov/pubmed/36710490 http://dx.doi.org/10.1177/15347354221151147 |
Ejemplares similares
-
Deciphering the Molecular Mechanism of Yifei-Sanjie Pill in Cancer-Related Fatigue
por: Wu, Yingchao, et al.
Publicado: (2023) -
Yifei Sanjie Formula Treats Chronic Obstructive Pulmonary Disease by Remodeling Pulmonary Microbiota
por: Wu, Yueying, et al.
Publicado: (2022) -
Zhengyuan capsules for the treatment of chemotherapy-induced cancer-related fatigue in stage IIIB–IV unresectable NSCLC: study protocol for a randomized, multi-center, double-blind, placebo-controlled clinical trial
por: Lin, Jietao, et al.
Publicado: (2022) -
A Network Pharmacology Approach to Explore the Potential Mechanisms of Yifei Sanjie Formula in Treating Pulmonary Fibrosis
por: Qiao, Bo, et al.
Publicado: (2020) -
Yifei sanjie Pills Alleviate Chemotherapy-Related Fatigue by Reducing Skeletal Muscle Injury and Inhibiting Tumor Growth in Lung Cancer Mice
por: Wu, Yingchao, et al.
Publicado: (2022)